

Pierre Johansen

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/5404924/pierre-johansen-publications-by-year.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22
papers

186
citations

9
h-index

12
g-index

26
ext. papers

267
ext. citations

3.6
avg, IF

3.29
L-index

#	Paper	IF	Citations
22	A population-adjusted indirect comparison of cardiovascular benefits of once-weekly subcutaneous semaglutide and dulaglutide in the treatment of patients with type 2 diabetes, with or without established cardiovascular disease. <i>Endocrinology, Diabetes and Metabolism</i> , 2021 , 4, e00259	2.7	4
21	Authors reply to Comment on "External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions". <i>Pharmacoeconomics</i> , 2021 , 39, 137-138	4.4	
20	Comparing the Cohort and Micro-Simulation Modeling Approaches in Cost-Effectiveness Modeling of Type 2 Diabetes Mellitus: A Case Study of the IHE Diabetes Cohort Model and the Economics and Health Outcomes Model of T2DM. <i>Pharmacoeconomics</i> , 2020 , 38, 953-969	4.4	10
19	A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release, Dulaglutide and Liraglutide in the UK. <i>Advances in Therapy</i> , 2020 , 37, 1248-1259	4.1	3
18	Days absent from work as a result of complications associated with type 2 diabetes: Evidence from 20 years of linked national registry data in Sweden. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1586-1597	6.7	9
17	Systematic Literature Review and Critical Appraisal of Health Economic Models Used in Cost-Effectiveness Analyses in Non-Alcoholic Steatohepatitis: Potential for Improvements. <i>Pharmacoeconomics</i> , 2020 , 38, 485-497	4.4	5
16	External Validation of the Core Obesity Model to Assess the Cost-Effectiveness of Weight Management Interventions. <i>Pharmacoeconomics</i> , 2020 , 38, 1123-1133	4.4	4
15	Efficacy of Once-Weekly Semaglutide vs Empagliflozin Added to Metformin in Type 2 Diabetes: Patient-Level Meta-analysis. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2020 , 105,	5.6	5
14	Evaluating the Long-Term Cost-Effectiveness of Once-Weekly Semaglutide Versus Once-Daily Liraglutide for the Treatment of Type 2 Diabetes in the UK. <i>Advances in Therapy</i> , 2020 , 37, 2427-2441	4.1	6
13	Management of Patients with Type 2 Diabetes with Once-Weekly Semaglutide Versus Dulaglutide, Exenatide ER, Liraglutide and Lixisenatide: A Cost-Effectiveness Analysis in the Danish Setting. <i>Diabetes Therapy</i> , 2019 , 10, 1297-1317	3.6	14
12	A Relative Cost of Control Analysis of Once-Weekly Semaglutide Versus Exenatide Extended-Release and Dulaglutide for Bringing Patients to HbA1c and Weight Loss Treatment Targets in the USA. <i>Advances in Therapy</i> , 2019 , 36, 1190-1199	4.1	5
11	Cost Effectiveness of Once-Weekly Semaglutide Versus Once-Weekly Dulaglutide in the Treatment of Type 2 Diabetes in Canada. <i>Pharmacoeconomics - Open</i> , 2019 , 3, 537-550	2.1	13
10	Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 611-621	6.7	21
9	Long-Term Clinical Benefits of Canagliflozin 100 mg Versus Sulfonylurea in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin in India. <i>Value in Health Regional Issues</i> , 2019 , 18, 65-73	1.6	2
8	Cost-Effectiveness Analysis of Canagliflozin 300mg Versus Dapagliflozin 10mg Added to Metformin in Patients with Type 2 Diabetes in the United States. <i>Diabetes Therapy</i> , 2018 , 9, 565-581	3.6	10
7	Incorporating Cardioprotective Effects of Once-Weekly Semaglutide in Estimates of Health Benefits for Patients with Type 2 Diabetes. <i>Diabetes</i> , 2018 , 67, 1273-P	0.9	5
6	Cost-Effectiveness of Once-Weekly Semaglutide 1.0 mg vs. Dulaglutide 1.5 mg as Add-On to Metformin in the Treatment of Type 2 Diabetes in Canada. <i>Diabetes</i> , 2018 , 67, 136-LB	0.9	3

5	Once-Weekly Semaglutide Provides Better Value for Money Than a Broad Range of Other Type 2 Diabetes Treatments in Canada: A Relative Cost of Control Analysis. <i>Canadian Journal of Diabetes</i> , 2018 , 42, S41	2.1	2
4	Validation of the Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). <i>Pharmacoeconomics</i> , 2017 , 35, 375-396	4.4	19
3	Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada. <i>Journal of Population Therapeutics and Clinical Pharmacology</i> , 2016 , 23, e151-68	3.3	7
2	Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. <i>Value in Health Regional Issues</i> , 2015 , 8, 8-19	1.6	13
1	Validation of the IHE Cohort Model of Type 2 Diabetes and the impact of choice of macrovascular risk equations. <i>PLoS ONE</i> , 2014 , 9, e110235	3.7	25